Recruiting

Phase 2

IloperidoneEvaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Sponsor:

Vanda Pharmaceuticals

Code:

NCT07090161

Conditions

Hypertension

Uncontrolled Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

iloperidone

Placebo

Study Details

Brief summary:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Conditions

Hypertension

Uncontrolled Hypertension

Study ID

NCT07090161

Start date

Sep 15, 2025

Status verified date

Jan, 2026

Completion date

Nov, 2026

Anticipated

Primary completion date

Oct, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion Criteria:

Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency

Study Design

Enrollment

240 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Experimental/Iloperidone

placebo comparator: Placebo Comparator

Interventions

iloperidone

Placebo

placebo comparator

Primary outcome measure

Change from baseline to treatment week 4 in SiSBP [ Time Frame: screening to treatment week 4 ]

Central Contacts and Locations

Central contacts

Vanda Pharmaceuticals, Inc.

202-734-3400 clinicaltrials@vandapharma.com

Locations

Vanda Investigative Site

Recruiting

Tempe, Arizona, United States, 85281

Vanda Investigative Site

Recruiting

Chula Vista, California, United States, 91910

Vanda Investigative Site

Recruiting

Dublin, California, United States, 94568

Vanda Investigative Site

Recruiting

Walnut Creek, California, United States, 94596

Vanda Investigative Site

Recruiting

Fort Myers, Florida, United States, 33912

Vanda Investigative Site

Recruiting

Columbus, Georgia, United States, 31904

Vanda Investigative Site

Recruiting

Oak Brook, Illinois, United States, 60523

Vanda Investigative Site

Recruiting

Tinley Park, Illinois, United States, 60477

Vanda Investigative Site

Recruiting

El Dorado, Kansas, United States, 67042

Vanda Investigative Site

Recruiting

Wichita, Kansas, United States, 67226

Vanda Investigative Site

Recruiting

Lexington, Kentucky, United States, 40509

Vanda Investigative Site

Recruiting

Hazelwood, Missouri, United States, 63042

Vanda Investigative Site

Recruiting

Kinston, North Carolina, United States, 28501

Vanda Investigative Site

Recruiting

Cincinnati, Ohio, United States, 45212

Vanda Investigative Site

Recruiting

Norman, Oklahoma, United States, 73069

Vanda Investigative Site

Recruiting

Charleston, South Carolina, United States, 29414

Vanda Investigative Site

Recruiting

Burke, Virginia, United States, 22015

Vanda Investigative Site

Recruiting

Norfolk, Virginia, United States, 23502

More Information

Sponsor

Vanda Pharmaceuticals

Last update posted

Feb 27, 2026

Last verified

Jan, 2026

Keywords

iloperidone
hypertension
uncontrolled hypertension

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Vanda Pharmaceuticals on 2026-02-27.